In a 2022 review (33), Galectin-3 was described as a potential therapeutic target in DCM, where it may exacerbate cardiac dysfunction by promoting myocardial fibrosis and inflammatory responses. This evidence concerns the gene LGALS3 and familial dilated cardiomyopathy.